Home >> Therapeutic Area >> Law >> Food & Beverage >>

Global Schizophrenia Therapeutics Market 2014-2018

Published: Nov-2014 | Format: PDF | Technavio | Number of pages: 102 | Code: MRS - 1565

About Schizophrenia

Schizophrenia is a chronic brain disorder that severely affects the quality of life of a patient by disturbing the normal functioning of the brain. Psychotic symptoms and a diminished range of expression of emotions are the characteristics of schizophrenia. 

 

The exact etiology of schizophrenia is still not known. In men, it appears in the late teens or early 20s, and in women in the late 20s or early 30s. However, most of the symptoms of this disorder can be managed with medication and psychological help.

TechNavio's analysts forecast the Global Schizophrenia Therapeutics market to grow at a CAGR of 2.82 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Schizophrenia Therapeutics market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of schizophrenia that are available in the market. The Global Schizophrenia Therapeutics market can be segmented into two: First-generation Antipsychotics and Second-generation Antipsychotics.

TechNavio's report, the Global Schizophrenia Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Schizophrenia Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

• Americas

• APAC

• EMEA     

  
Key Vendors

• AstraZeneca

• Bristol-Myers Squibb

• Eli Lily

• F. Hoffmann-La Roche

• H. Lundbeck

• Johnson & Johnson

• Otsuka Pharmaceuticals

• Pfizer

• Sumitomo Dainippon Pharma

Other Prominent Vendors

• Abbott Laboratories

• Acadia Pharmaceuticals

• Alkermes

• Astellas Pharma

• Chugai Pharmaceutical

• Glaxo Smith Kline

• Merck

• Mitsubishi Tanabe Pharma

• Novartis

• Takeda Pharmaceutical

Market Driver

• Increase in Aging Population

• For a full, detailed list, view our report

Market Challenge

• Increase in Generic Competition

• For a full, detailed list, view our report

Market Trend

• Rising Awareness of Schizophrenia

• For a full, detailed list, view our report

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be

• What are the key market trends

• What is driving this market

• What are the challenges to market growth

• Who are the key vendors in this market space

• What are the market opportunities and threats faced by the key vendors

• What are the strengths and weaknesses of the key vendors

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Schizophrenia Therapeutics Market in the US

06.3.1 Market Size and Forecast

06.4 Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

08.1.1 US

09. Types of Schizophrenia

10. Phases of Schizophrenia

11. Market Segmentation by Drug Class

12. Geographical Segmentation

12.1 Schizophrenia Therapeutics Market in Americas

12.1.1 Market Size and Forecast

12.2 Schizophrenia Therapeutics Market in the APAC Region

12.2.1 Market Size and Forecast

12.3 Schizophrenia Therapeutics Market in the EMEA Region

12.3.1 Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2013

20.3 Other Prominent Vendors

21. Key Vendor Analysis

21.1 AstraZeneca

21.1.1 Key Facts

21.1.2 Business Description

21.1.3 Business Segmentation

21.1.4 Business Strategy

21.1.5 Revenue by Business Segmentation

21.1.6 Revenue Comparison 2011-2013

21.1.7 Sales Revenue by Geographical Segmentation

21.1.8 Key Developments

21.1.9 SWOT Analysis

21.2 Bristol-Myers Squibb Co.

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Product Segmentation

21.2.4 Sales by Geography

21.2.5 Business Strategy

21.2.6 Key Information

21.2.7 SWOT Analysis

21.3 Eli Lilly and Co.

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation by Revenue 2013

21.3.4 Business Segmentation by Revenue 2012 and 2013

21.3.5 Sales by Geography

21.3.6 Business Strategy

21.3.7 Key Developments

21.3.8 SWOT Analysis

21.4 F. Hoffmann-La Roche

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Business Segmentation

21.4.4 Business Segmentation by Revenue 2012 and 2013

21.4.5 Geographical Segmentation by Revenue

21.4.6 Business Strategy

21.4.7 Key Information

21.4.8 SWOT Analysis

21.5 H. Lundbeck

21.5.1 Key Facts

21.5.2 Business Overview

21.5.3 Product Segmentation by Revenue 2013

21.5.4 Product Segmentation by Revenue 2012 and 2013

21.5.5 Geographical Segmentation by Revenue 2013

21.5.6 Business Strategy

21.5.7 Recent Developments

21.5.8 SWOT Analysis

21.6 Johnson & Johnson

21.6.1 Key Facts

21.6.2 Business Overview

21.6.3 Business Segmentation by Revenue 2013

21.6.4 Business Segmentation by Revenue 2012 and 2013

21.6.5 Geographical Segmentation by Revenue 2013

21.6.6 Business Strategy

21.6.7 Recent Developments

21.6.8 SWOT Analysis

21.7 Otsuka Pharmaceuticals

21.7.1 Key Facts

21.7.2 Business Overview

21.7.3 Business Segmentation by Revenue 2014

21.7.4 Business Segmentation by Revenue 2013 and 2014

21.7.5 Geographical Segmentation by Revenue 2014

21.7.6 Business Strategy

21.7.7 Recent Developments

21.7.8 SWOT Analysis

21.8 Pfizer Inc.

21.8.1 Key Facts

21.8.2 Business Description

21.8.3 Business Segmentation

21.8.4 Revenue by Business Segmentation

21.8.5 Revenue Comparison 2012 and 2013

21.8.6 Sales by Geography

21.8.7 Business Strategy

21.8.8 Key Developments

21.8.9 SWOT Analysis

21.9 Sumitomo Dainippon Pharma

21.9.1 Key Facts

21.9.2 Business Overview

21.9.3 Product Segmentation

21.9.4 Products Segmentation by Revenue 2013 and 2014

21.9.5 Business Strategy

21.9.6 Recent Developments

21.9.7 SWOT Analysis

22. Other Reports in this Series

List of Exhibits:


Exhibit 1: Market Research Methodology
Exhibit 2: Global Schizophrenia Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Schizophrenia Therapeutics Market in the US
Exhibit 4: Types of Schizophrenia
Exhibit 5: Phases of Schizophrenia
Exhibit 6: Global Schizophrenia Therapeutics Market Segmentation by Drug Class
Exhibit 7: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013
Exhibit 8: Schizophrenia Therapeutics Market in America 2013-2018 (US$ billion)
Exhibit 9: Schizophrenia Therapeutics Market in the APAC Region 2013-2018 (US$ billion)
Exhibit 10: Schizophrenia Therapeutics Market in the EMEA Region 2013-2018 (US$ billion)
Exhibit 11: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (US$ billion)
Exhibit 12: Global Schizophrenia Therapeutics Market by Geographical Segmentation 2013-2018 (in percent)
Exhibit 13: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 14: AstraZeneca: Business Segmentation
Exhibit 15: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 16: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 17: AstraZeneca: Sales Revenue  by Geographical Segmentation 2013
Exhibit 18: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
Exhibit 19: Bristol-Myers Squibb Co.: Sales by Geography 2013
Exhibit 20: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 21: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 22: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 23: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 24: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 25: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 26: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 27: H. Lundbeck: Business Segmentation by Revenue 2013
Exhibit 28: H. Lundbeck: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 29: H. Lundbeck: Geographical Segmentation by Revenue 2013
Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 32: Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 33: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
Exhibit 34: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 35: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 36: Pfizer Inc.: Business Segmentation
Exhibit 37: Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 38: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 39: Pfizer Inc.: Revenue by Geography 2013
Exhibit 40: Sumitomo Dainippon Pharma: Product Segmentation 2014
Exhibit 41: Sumitomo Dainippon Pharma: Product Segmentation by Revenue 2013 and 2014

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2500 View Pricing